Drug intelligence / Profile preview

CD-GA-102

Development stage: Phase 1
Modality: RNA Therapeutics → Nucleic Acid Therapeutics
Administration: Intravenous

Overview

CD-GA-102 is an experimental therapeutic agent based on self-replicating RNA (srRNA) designed to facilitate the expression of hepatocyte nuclear factor 4 alpha (HNF4α). It is being investigated for use in oncology, specifically for the treatment of colorectal cancer. CD-GA-102 is administered via peripheral intravenous injection at a defined dose level in clinical studies. While detailed mechanism-of-action data are limited, it is closely related to HNF4α-targeted srRNA agents, which are under evaluation for their capacity to reprogram the tumor microenvironment and exert anti-tumor effects by restoring or enhancing tumor suppressor pathways through HNF4α induction[4][2].

Targets

HNF4A (Hepatocyte nuclear factor 4 alpha)

Beyond the preview

Go deeper on CD-GA-102.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CD-GA-102.

Explore the full profile